The effects of nano curcumin in diabetic peripheral neuropathy

The effects of nano curcumin supplementation in diabetic peripheral neuropathy

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20210925052566N2

Enrollment

100

Registered

2022-03-29

Start date

2022-05-21

Completion date

Unknown

Last updated

2022-04-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes mellitus. Diabetes mellitus due to underlying condition with diabetic neuropathy, unspecified

Interventions

Intervention 1: Intervention group: nanocurcumin. Intervention 2: Control group: placebo.

Eligibility

Sex/Gender

All

Age

30 Years to 70 Years

Inclusion criteria

Inclusion criteria: Patients will eligible for recruitment with a MNSI of 2 or higher, abnormal NCS results and normal folate, vitamin B12 levels.

Exclusion criteria

Exclusion criteria: Exclusion criteria will be uncontrolled diabetes (HbA1c>8.5%), current pregnancy or lactating women, alcohol intake, current smoker, diabetic foot , mental disease, heart failure, cancer, evidence of liver disease (such as viral hepatitis, autoimmune hepatitis, etc.), impaired renal (GFR < 30), sensitivity to turmeric supplementation, current use of warfarin or other anticoagulant agents, and those with symptomatic peripheral vascular disease.

Design outcomes

Primary

Measure	Time frame
1. Michigan neuropathy screening instrument (MNSI). Timepoint: Baseline and 16 weeks. Method of measurement: Using standard scoring systems and questionnaires. Scoring is: Michigan neuropathy screening instrument , (0-10).;Neuropathy disability score (NDS). Timepoint: Baseline and 16 weeks. Method of measurement: Using standard scoring systems and questionnaires. Scoring is: Neuropathy disability score (0-10).	—

Measure

Time frame

1. Michigan neuropathy screening instrument (MNSI). Timepoint: Baseline and 16 weeks. Method of measurement: Using standard scoring systems and questionnaires. Scoring is: Michigan neuropathy screening instrument , (0-10).;Neuropathy disability score (NDS). Timepoint: Baseline and 16 weeks. Method of measurement: Using standard scoring systems and questionnaires. Scoring is: Neuropathy disability score (0-10).

—

Secondary

Measure	Time frame
Pain score. Timepoint: Baseline and 16 weeks. Method of measurement: Patients will be asked to score pain on a visual analog scale 0-10 with 10 being the worst pain ever.;Fasting glucose, serum insulin, HOMA –IR, and HBA1c. Timepoint: Baseline and 16 weeks. Method of measurement: lab kit.;Lipid profiles (HDL-c, LDL-c, TG, TC). Timepoint: Baseline and 16 weeks. Method of measurement: lab kit.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSayed Mahmoud Sajjadi Jazi

Tehran University of Medical Sciences

mahmood.sajadi@gmail.com09802188220071

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026